Drug
Mocetinostat
Mocetinostat: highest development phase Phase 2, developed by Mirati Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mocetinostat NCT02236195 | Phase 2 | Urothelial Carcinoma |
| Mocetinostat - 50 mg NCT02805660 | Phase 1/2 | Advanced Cancer |
| Mocetinostat NCT02993991 | Phase 1 | Squamous Cell Carcinoma, Head And Neck |
Latest
No recent events.
Follow Mocetinostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.